Incorporating one or two costimulatory domains, such as CD28, 4-1BB, CD27, OX40, and ICOS, into the CAR structure significantly enhanced T cell proliferation, persistence, and anti-tumor efficacy in vivo [121, 123, 124]. Here, CD28 is linked to neoplasm.